数据链接：
官方服务：
资源简介：
Analyze Clinical Trials data for PROC
针对PROC的临床试验数据分析
应用场景：
创建时间：
2022-02-02
相关数据集
Fig8
Schematic illustration of eNK-EXO enhance the anti-tumor effects against ovarian cancer by delivering chemotherapeutic drugs and reactivating NK cell functions
NIAID Data Ecosystem80
ARID1A-mutated ovarian cancers depend on HDAC6 activity
ARID1A, encoding a subunit of the SWI/SNF chromatin remodeling complex, is the most mutated epigenetic regulator in human cancers. ARID1A and TP53 mutations are typically mutually exclusive. Therap
NIAID Data Ecosystem40
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review
Due to its anti-angiogenic properties, trebananib is frequently employed in the treatment of cancer patients, particularly those with ovarian cancer. We conducted a meta-analysis to assess the efficac
NIAID Data Ecosystem10
Complete list of synlet interactions addressed by novel drug combinations.
The full list of addressed synlet interactions as well as the respective novel proposed drug combinations are given in the S1 Table. Synlet interactions are sorted in descending order based on the sum
NIAID Data Ecosystem50
Table_1_A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy.DOCX
Background: Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related deaths worldwide. Preclinical studies found that copper-lowering agents could re-sensitize platinum-res
NIAID Data Ecosystem30
